BerGenBio

Carnegie Investment Bank is proud to have acted as joint manager in connection with BerGenBio ASA’s NOK 250 million rights issue.
 
The rights issue had strong support from existing shareholders and attracted interest from new investors. Net proceeds from the rights issue and exercised warrants will be used to further advance the company’s strategy for non-small cell lung cancer (“NSCLC”), severe respiratory infections and general corporate purposes.
 
Carnegie congratulates Martin Olin and Runde Skeie and the rest of the BerGenBio team with the transaction and we look forward to continuing our support of BerGenBio going forward.